Iceland· IS-EU/1/08/502/001
Mepact
A mifamurtid product containing mifamurtidum inn, registered in Iceland by Esteve Pharmaceuticals S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Mifamurtid is registered in 8 of 19 countries.
Countries holding a registration under ATC L03AX15 (mifamurtid), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 5 of them publish a price we can compare per daily dose
Mifamurtid · ATC L03AX15
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Mifamurtidum INN
- Manufacturer
- Esteve Pharmaceuticals S.A.
- Country
- Iceland (IS)
- ATC code
- L03AX15
- ATC class
- Mifamurtid
- Defined daily dose
- 0.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mifamurtid in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMepact 4mg powder for concentrate for dispersion for infusion vialsTakeda UK Ltd
- CzechiaMEPACTEsteve Pharmaceuticals S.A., Barcelona
- SpainMEPACT 4 mg POLVO PARA SUSPENSION PARA PERFUSIONEsteve Pharmaceuticals S.A.
- FinlandMEPACTEsteve Pharmaceuticals, S.A
- IrelandMepact 4 mg Powder for concentrate for dispersion for infusionEsteve Pharmaceuticals S.A.
- NetherlandsMepact, poeder voor suspensie voor intraveneuze infusie, 4 mgEsteve Pharmaceuticals S.A.
- PolandMepactEsteve Pharmaceuticals, S.A.
- BelgiumMepact 4 mgEsteve Pharmaceuticals
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Mepact
- Norway · Mepact
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4ba605d0-fa6b-4493-9f85-bfd9f3784fe2 GET /v1/drugs/4ba605d0-fa6b-4493-9f85-bfd9f3784fe2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Frostþurrkað stungulyf, dreifa",
"source": "lyfjastofnun",
"atc_raw": "L03AX15",
"marketed": false,
"strength": "4 mg",
"ma_number": "EU/1/08/502/001",
"substance": "Mifamurtidum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "39952"
}See everything about mifamurtid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.